Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

被引:85
|
作者
Lestner, Jodi [1 ]
Hope, William W. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, London, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GE, Merseyside, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
antifungal; itraconazole; pharmacodynamics; pharmacokinetics; toxicodynamics; RESISTANT ASPERGILLUS-FUMIGATUS; HYDROXYPROPYL-BETA-CYCLODEXTRIN; STEADY-STATE PHARMACOKINETICS; DRUG-DRUG INTERACTION; CANDIDA-ALBICANS; DISEASES-SOCIETY; IN-VITRO; PRACTICE GUIDELINES; ORAL ITRACONAZOLE; AZOLE RESISTANCE;
D O I
10.1517/17425255.2013.794785
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Fungal infections are a major source of global morbidity and mortality. Itraconazole is a triazole antifungal agent that is widely used for the prevention and treatment of fungal infection. While newer antifungal agents are now available, itraconazole is an orally bioavailable agent with broad-spectrum antifungal activity. Itraconazole remains a useful drug for the management of allergic and invasive mycoses worldwide. Areas covered: This article provides a summary of the pharmacokinetics, pharmacodynamics and clinical uses of itraconazole. Additionally, the authors summarise the safety and recently described toxicodynamics and discuss the value of therapeutic drug monitoring (TDM) with itraconazole. The following search criteria were constructed in order to identify relevant literature using PubMed and Ovid-MEDLINE: itraconazole, triazole, pharmacokinetics, pharmacodynamics, toxicodynamics and TDM. Relevant abstracts and articles identified from reviewing secondary citations were additionally retrieved and included if relevant. Expert opinion: Itraconazole remains an important agent in the prevention and treatment of fungal infection. Itraconazole has a broad-spectrum of activity and is available in both an intravenous and oral form making long-term use in chronic mycoses practical. Itraconazole is widely used for the treatment of endemic fungal infections. Pharmacokinetic variability and clinically important drug interactions make TDM of itraconazole an important consideration.
引用
收藏
页码:911 / 926
页数:16
相关论文
共 50 条
  • [1] An update on the global treatment of invasive fungal infections
    Munzen, Melissa E.
    Goncalves Garcia, Ariana D.
    Martinez, Luis R.
    FUTURE MICROBIOLOGY, 2023, 18 (15) : 1095 - 1117
  • [2] Clinical trials with itraconazole as a treatment for chytrid fungal infections in amphibians
    Brannelly, Laura A.
    Richards-Zawacki, Corinne L.
    Pessier, Allan P.
    DISEASES OF AQUATIC ORGANISMS, 2012, 101 (02) : 95 - 104
  • [3] Use of posaconazole in the treatment of invasive fungal infections
    Mehta, Aneesh K.
    Langston, Amelia A.
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (06) : 619 - 630
  • [4] Clinical practices for treatment of invasive fungal infections
    Szekely-Loria, A.
    Jansen, C.
    Mouton-Rioux, V.
    Datry, A.
    Fievet, M. -H.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 437 - 438
  • [5] Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
    Robin de Vries
    Simon Daenen
    Keith Tolley
    Axel Glasmacher
    Archie Prentice
    Sarah Howells
    Hariette Christopherson
    Lolkje T. W. de Jong-van den Berg
    Maarten J. Postma
    PharmacoEconomics, 2008, 26 : 75 - 90
  • [6] Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    de Vries, Robin
    Daenen, Simon
    Tolley, Keith
    Glasmacher, Axel
    Prentice, Archie
    Howells, Sarah
    Christopherson, Hariette
    de Jong-van den Berg, Lolkje T. W.
    Postma, Maarten J.
    PHARMACOECONOMICS, 2008, 26 (01) : 75 - 90
  • [7] Clinical experience with itraconazole in systemic fungal infections
    Boogaerts, M
    Maertens, J
    DRUGS, 2001, 61 (Suppl 1) : 39 - 47
  • [8] Clinical Experience with Itraconazole in Systemic Fungal Infections
    Marc Boogaerts
    Johan Maertens
    Drugs, 2001, 61 : 39 - 47
  • [9] PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING
    Kanbur, B.
    Sarioz, F.
    Tatar, F.
    VALUE IN HEALTH, 2008, 11 (06) : A434 - A434
  • [10] ITRACONAZOLE IN THE TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS
    DENNING, DW
    MEDIZINISCHE KLINIK, 1991, 86 : 3 - 4